Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders

Abstract

Compositions and methods for treatment of focal muscle spasms. Immunotoxin conjugates comprise a toxin conjugated to an antibody reactive to a muscle specific antigen.

1 - 11 . (canceled)  
   
   
       12 . An immunotoxin conjugate, comprising an antibody conjugated to a cellular toxin selected from the group consisting of: ricin and abrin, wherein said antibody of said immunotoxin conjugate is selectively reactive, under immunologically reactive conditions, to a mammalian nicotinic acetylcholine receptor of a muscle cell of a muscle of a mammal and whereupon said selective reaction said cellular toxin of said immunotoxin conjugate mediates the death of said muscle cell.  
   
   
       13 . The immunotoxin of  claim 12 , wherein the antibody is a monoclonal antibody.  
   
   
       14 . The immunotoxin conjugate of  claim 12 , wherein said mammalian acetylcholine receptor is a human acetylcholine receptor.  
   
   
       15 . The immunotoxin conjugate of  claim 12 , wherein said toxin is ricin.  
   
   
       16 . The immunotoxin conjugate of  claim 12 , wherein said muscle exhibits a focal muscle spasm selected from the group consisting of: blepharospasm, cervical dystonia, hand dystonia, limb dystonia, hemifacial spasm, bruxism, strabismus, VI nerve palsy, spasmodic dysphonia, and oromandibular dystonia.  
   
   
       17 . The immunotoxin conjugate of  claim 12 , wherein said conjugate is dissolved in a pharmaceutically acceptable carrier suitable for intramuscular administration to said mammal.  
   
   
       18 . An immunotoxin conjugate, comprising an antibody conjugated to a galactose binding moiety and a cellular toxin selected from the group consisting of: ricin-A and abrin-A, wherein said antibody of said immunotoxin conjugate is selectively reactive, under immunologically reactive conditions, to a mammalian nicotinic acetylcholine receptor of a muscle cell of a muscle of a mammal and whereupon said selective reaction said cellular toxin of said immunotoxin conjugate mediates the death of said muscle cell.  
   
   
       19 . The immunotoxin conjugate of  claim 18 , wherein said galactose binding moiety is selected from the group consisting of: ricin-B and abrin-B.  
   
   
       20 . The immunotoxin conjugate of  claim 18 , wherein said antibody is a monoclonal antibody.  
   
   
       21 . The immunotoxin conjugate of  claim 18 , wherein said mammalian acetylcholine receptor is a human acetylcholine receptor.  
   
   
       22 . immunotoxin conjugate of  claim 18 , wherein said toxin is ricin.  
   
   
       23 . The immunotoxin conjugate of  claim 18 , wherein said muscle exhibits a focal muscle spasm selected from the group consisting of: blepharospasm, cervical dystonia, hand dystonia, limb dystonia, hemifacial spasm, bruxism, strabismus, VI nerve palsy, spasmodic dysphonia, and oromandibular dystonia.  
   
   
       24 . The immunotoxin conjugate of  claim 18 , wherein said conjugate is dissolved in a pharmaceutically acceptable carrier suitable for intramuscular administration to said mammal.